Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation

Frontiers in Medicine

article

Blanka Mezö¹  Orsolya Horváth²  György Sinkovits¹  Nóra Veszeli¹  Gergely Kriván²  Zoltán Prohászka¹ 

[1] Research Laboratory, MTA-SE Research Group of Immunology and Hematology, Department of Internal Medicine and Hematology, Hungarian Academy of Sciences, Semmelweis University;Pediatric Hematology and Bone Marrow Transplantation Unit, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases

关键词: hematopoietic stem cell transplantation;    HSCT;    transplant-associated thrombotic microangiopathy;    TA-TMA;    complement;    pediatric;    sC5b-9;    thrombotic microangioapathy;   

DOI  :  10.3389/fmed.2020.569291

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA) is a multifactorial complication. Complement dysregulation may play an important role in the pathogenesis of TA-TMA. Our previous observations suggested that early increase of soluble C5b-9 (sC5b-9), before the development of other complications, can predict the development of later TA-TMA. The present study aims to validate our earlier findings in an independent cohort enrolling 67 pediatric patients who underwent allogeneic HSCT during the study period (October 2015–January 2019). Five different TA-TMA diagnostic criteria were applied, and all important clinical and laboratory parameters of TA-TMA activity were registered. Complement pathway activities, components and sC5b-9 levels were systematically measured before transplantation and on days 28, 56, and 100 after HSCT. A strong and remarkable association still have been found between early increase of sC5b-9 (10 of 10 patients with TA-TMA vs. 27 of 57 without TA-TMA; P = 0.002) and the development of TA-TMA during 100 days post-transplantation. An increase in sC5b-9 concentration had 100% sensitivity and 53% specificity for TA-TMA in the cohort. All TA-TMA cases have been observed during cyclosporine immunosuppression, no TA-TMA was diagnosed during tacrolimus or mycophenolat mofetil therapy. In the majority of patients TA-TMA was mild and self-limiting, without any signs of organ damage. No additional complement parameters were closely associated with the development of TA-TMA. Early raise of the sC5b-9 activation marker was predictive for later development of TA-TMA throughout the whole study period. In patients with a marked increase, early and frequent monitoring of TA-TMA activity markers should be attempted, to facilitate subsequent therapy decisions in time. However, patients with TA-TMA were only identified during or after cyclosporine immunosuppression. Further studies enrolling higher number of patients are necessary to determine the role of immunosuppression in the pathogenesis of TA-TMA.

【 授权许可】

CC BY